Get the latest news on Zelluna stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on ULTMF performance

Latest Zelluna Stock News | OTC:ULTMF | Benzinga

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Comments

Zelluna Stock News

News

Latest Zelluna Stock News | OTC:ULTMF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga